

PROVIDER BULLETIN

PROVIDER INFORMATION



May 1, 2023

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-753	Cardiac Contractility Modulation
MP-451	Intravitreal and Punctum Corticosteroid Implants
MP-718	Neuromuscular Electrical Stimulation (NMES)
MP-755	Digital Health Technologies: Therapeutic Applications
MP-685	Gender Affirming Procedures
MP-753	Cardiac Contractility Modulation

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
PH-90696	Lamzede® (velmanase alfa-tycv)
PH-90026	Eylea® (aflibercept)
PH-90177	Ilaris® (canakinumab)
PH-9401	Spravato® (esketamine)
PH-90660	Enjaymo™ (sutimlimab-jome)
PH-90158	Krystexxa® (pegloticase)
PH-90183	Levoleucovorin: Fusilev®; Khapzory™
PH-90650	Tezspire® (tezepelumab-ekko)
PH-400	Botulinum Toxin